Safety, tolerability and risk benefit analysis of tiotropium in COPD

International Journal of COPD

Volumn 3, Issue 4, 2008, Pages 575-584

  Oba, Yuji ^a   Zaza, Tareq ^a   Thameem, Danish M ^a  

^a University of Missouri   (United States)

Author keywords

Bronchodilator agents; Lung diseases; Obstructive; Tiotropium bromide

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE PLUS FORMOTEROL; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; FLUTICASONE; FLUTICASONE PROPIONATE PLUS SALMETEROL; FORMOTEROL; FORMOTEROL FUMARATE; IPRATROPIUM BROMIDE; LONG ACTING DRUG; SALBUTAMOL; SALMETEROL; SHORT ACTING DRUG; TIOTROPIUM BROMIDE;

ANGINA PECTORIS; ANGIONEUROTIC EDEMA; ANTICHOLINERGIC EFFECT; BLURRED VISION; BRONCHODILATATION; BRONCHOSPASM; CANDIDIASIS; CARDIOVASCULAR DISEASE; CATARACT; CEREBROVASCULAR ACCIDENT; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CLOSED ANGLE GLAUCOMA; CONSTIPATION; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DRUG ABSORPTION; DRUG ERUPTION; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; EDEMA; EPISTAXIS; GLAUCOMA; HEART ARRHYTHMIA; HEART DEATH; HEART DISEASE; HEART INFARCTION; HEART PALPITATION; HUMAN; INTRAOCULAR PRESSURE; LUNG FUNCTION; MYALGIA; PARALYTIC ILEUS; PATIENT COMPLIANCE; PATIENT SATISFACTION; PHARYNGITIS; PNEUMONIA; QUALITY OF LIFE; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; SINUSITIS; SMOOTH MUSCLE RELAXATION; TACHYCARDIA; TACHYPHYLAXIS; THORAX PAIN; THROAT IRRITATION; TREMOR; URINARY TRACT INFECTION; URINE RETENTION; VOMITING; XEROSTOMIA;

ADMINISTRATION, INHALATION; BRONCHODILATOR AGENTS; CARDIOVASCULAR DISEASES; CHOLINERGIC ANTAGONISTS; HUMANS; MEDICATION ADHERENCE; PATIENT SATISFACTION; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY OF LIFE; RISK ASSESSMENT; SCOPOLAMINE DERIVATIVES; TREATMENT OUTCOME;

EID: 60249090111     PISSN: 11769106     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (62)

1. Anthonisen NR, Connett JE, Enright PL, et al. 2002. Hospitalizations and mortality in the Lung Health Study. Am J Respir Crit Care Med, 166:333-9.
2. Anthonisen NR, Skeans MA, Wise RA, et al. 2005. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med, 142:233-9.
3. Barnes PJ. 2000. The pharmacological properties of tiotropium. Chest, 117:63S-66.
4. Barr RG. Management of chronic obstructive pulmonary disease. 2004. JAMA, 291:1066-7; author reply 1067.
5. Barr RG, Bourbeau J, Camargo CA, et al. 2006. Tiotropium for stable chronic obstructive pulmonary disease: A meta-analysis. Thorax, 61:854-62.
6. Bateman ED, van Dyk M, Sagriotis A. 2008. Comparable spirometric efficacy of tiotropium compared with salmeterol plus fluticasone in patients with COPD: a pilot study. Pulm Pharmacol Ther, 21:20-5.
7. Bender BG, Pedan A, Varasteh LT. 2006. Adherence and persistence with fluticasone propionate/salmeterol combination therapy. J Allergy Clin Immunol, 118:899-904.
8. Breekveldt-Postma NS, Gerrits CM, Lammers JW, et al. 2004. Persistence with inhaled corticosteroid therapy in daily practice. Respir Med, 98:752-9.
9. Breekveldt-Postma NS, Koerselman J, Erkens JA, et al. 2007. Enhanced persistence with tiotropium compared with other respiratory drugs in COPD. Respir Med, 101:1398-405.
10. Briggs DD Jr, Covelli H, Lapidus R, et al. 2005. Improved daytime spirometric efficacy of tiotropium compared with salmeterol in patients with COPD. Pulm Pharmacol Ther, 18:397-404.
11. Brusasco V, Hodder R, Miravitlles M, et al. 2003. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax, 58:399-404.
12. Calverley PM, Anderson JA, Celli B, et al. 2007. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med, 356:775-89.
13. Casaburi R, Briggs DD, Jr., Donohue JF, et al. 2000. The spirometric efficacy of once-daily dosing with tiotropium in stable COPD: a 13-week multicenter trial. The US Tiotropium Study Group. Chest, 118:1294-302.
14. Casaburi R, Kukafka D, Cooper CB, et al. 2005. Improvement in exercise tolerance with the combination of tiotropium and pulmonary rehabilitation in patients with COPD. Chest, 127:809-17.
15. Casaburi R, Mahler DA, Jones PW, et al. 2002. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J, 19:217-24.
16. Celli BR, MacNee W. 2004. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J, 23:932-46.
17. Chan CK, Maltais F, Sigouin C, et al. 2007. A randomized controlled trial to assess the efficacy of tiotropium in Canadian patients with chronic obstructive pulmonary disease. Can Respir J, 14:465-72.
18. Chapman KR. 1990. The role of anticholinergic bronchodilators in adult asthma and chronic obstructive pulmonary disease. Lung, 168:295-303.
19. COMBIVENT Inhalation Aerosol Study Group. 1994. In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone. An 85-day multicenter trial. Chest, 105:1411-9.
20. Covelli H, Bhattacharya S, Cassino C, et al. 2005. Absence of electrocardiographic findings and improved function with once-daily tiotropium in patients with chronic obstructive pulmonary disease. Pharmacotherapy, 25:1708-18.
21. Cramer JA, Bradley-Kennedy C, Scalera A. 2007. Treatment persistence and compliance with medications for chronic obstructive pulmonary disease. Can Respir J, 14:25-9.
22. Criner GJ, Sharafkhaneh A, Player R, et al. 2008. Efficacy of tiotropium inhalation powder in african-american patients with chronic obstructive pulmonary disease. COPD, 5:35-41.
23. Dahl R, Greefhorst LA, Nowak D, et al. 2001. Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 164:778-84.
24. Disse B, Reichl R, Speck G, et al. 1993. Ba 679 BR, a novel long-acting anticholinergic bronchodilator. Life Sci, 52:537-44.
25. Donohue JF, Menjoge S, Kesten S. 2003. Tolerance to bronchodilating effects of salmeterol in COPD. Respir Med, 97:1014-20.
26. Donohue JF, van Noord JA, Bateman ED, et al. 2002. A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest, 122:47-55.
27. Dusser D, Bravo ML, Iacono P. 2006. The effect of tiotropium on exacerbations and airflow in patients with COPD. Eur Respir J, 27:547-55.
28. Ernst P, Gonzalez AV, Brassard P, et al. 2007. Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia. Am J Respir Crit Care Med, 176:162-6.
29. Fishman A, Martinez F, Naunheim K, et al. 2003. A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. N Engl J Med, 348:2059-73.
30. Food and Drug Administration. 2002. Pulmonary-Allergy Drugs Advisory Committee. 2002 Clinical briefing document. Integrated review of safety, NDA, 21-395.
31. Food and Drug Administration. 2005. FDA Public Health Advisory. Serevent Diskus (salmeterol xinafoate inhalation powder), Advair Diskus (fluticasone propionate and salmeterol inhalation powder), Foradil Aerolizer (formoterol fumarate inhalation powder). Accessed October, 2008.URL: http://www.fda.gov/cder/drug/advisory/LABA.htm.
32. Food and Drug Administration. 2008. Early Communication about an Ongoing Safety Review of Tiotropium. Accessed October, 2008.URL: http://www.fda.gov/cder/drug/early_comm/tiotropium.htm.
33. GlaxoSmithKline. 2005. Clinical trial register for a multicenter, randomized, double-blind,double-dummy, parallel group, 8-week comparison of salmeterol xinafoate versus ipratropium bromide versus salmeterol xinafoate plus ipratropium bromide versus placebo in subjects with chronic obstructive pulmonary disease. Accessed October, 2008. URL: http://www.gsk-clinicalstudyregister.com/files/pdf/2981.pdf.
34. GlaxoSmithKline. 2005. Clinical trial register for a multicenter, randomized, double-blind,double-dummy, parallel-group, 8-week comparison of salmeterol xinafoate versus ipratropium bromide versus salmeterol xinafoate plus ipratropium bromide versus placebo in subjects with chronic obstructive pulmonary disease. Accessed October, 2008. URL: http://www.gsk-clinicalstudyregister.com/files/pdf/2843.pdf
35. Gross NJ, Skorodin MS. 1984. Role of the parasympathetic system in airway obstruction due to emphysema. N Engl J Med, 311:421-5.
36. Kesten S, Jara M, Wentworth C, et al. 2006. Pooled clinical trial analysis of tiotropium safety. Chest, 130:1695-703.
37. Krigsman K, Nilsson JL, Ring L. 2007. Refill adherence for patients with asthma and COPD: comparison of a pharmacy record database with manually collected repeat prescriptions. Pharmacoepidemiol Drug Saf, 16:441-8.
38. Lee TA, Pickard AS, Au DH, et al. 2008. Risk for death associated with medications for recently diagnosed chronic obstructive pulmonary disease. Ann Intern Med, 149(6):380-90.
39. Mahler DA, Donohue JF, Barbee RA, et al. 1999. Efficacy of salmeterol xinafoate in the treatment of COPD. Chest, 115:957-65.
40. Medical Research Council Working Party. 1981. Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Lancet, 1:681-6.
41. 1 in patients with COPD irrespective of smoking status. Pulm Pharmacol Ther, 21:146-51.
42. National Collaborating Centre for Chronic Conditions. 2004 Chronic obstructive pulmonary disease. National clinical guideline on management of chronic obstructive pulmonary disease in adults in primary and secondary care. Thorax, 59(Suppl 1):1-232.
43. Nichol KL, Baken L, Nelson A. 1999. Relation between influenza vaccination and outpatient visits, hospitalization, and mortality in elderly persons with chronic lung disease. Ann Intern Med, 130:397-403.
44. Niewoehner DE, Rice K, Cote C, et al. 2005. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial. Ann Intern Med, 143:317-26.
45. Nocturnal Oxygen Therapy Trial Group. 1980. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Nocturnal Oxygen Therapy Trial Group. Ann Intern Med, 93:391-8.
46. Oba Y. 2007. Cost-effectiveness of long-acting bronchodilators for chronic obstructive pulmonary disease. Mayo Clin Proc, 82:575-82.
47. Pauwels RA, Buist AS, Calverley PM, et al. 2001. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med, 163:1256-76.
48. Powrie DJ, Wilkinson TM, Donaldson GC, et al. 2007. Effect of tiotropium on sputum and serum inflammatory markers and exacerbations in COPD. Eur Respir J, 30:472-8.
49. Qaseem A, Snow V, Shekelle P, et al. 2007. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline from the American College of Physicians. Ann Intern Med, 147:633-8.
50. Rabe KF, Hurd S, Anzueto A, et al. 2007. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med, 176:532-55.
51. Rand CS, Nides M, Cowles MK, et al. 1995. Long-term metered-dose inhaler adherence in a clinical trial. The Lung Health Study Research Group. Am J Respir Crit Care Med, 152:580-8.
52. Rennard SI, Anderson W, ZuWallack R, et al. 2001. Use of a long-acting inhaled beta2-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 163:1087-92.
53. Salpeter SR, Ormiston TM, Salpeter EE. 2004. Cardiovascular effects of beta-agonists in patients with asthma and COPD: a meta-analysis. Chest, 125:2309-21.
54. Sestini P, Renzoni E, Robinson S, et al. 2002. Short-acting beta 2 agonists for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev: CD001495.
55. Singh S, Loke YK, Furberg CD. 2008. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA, 300:1439-50.
56. Tashkin DP, Celli B, Senn S, et al. 2008. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med, 359:1543-54.
57. van Noord JA, Smeets JJ, Custers FL, et al. 2002. Pharmacodynamic steady state of tiotropium in patients with chronic obstructive pulmonary disease. Eur Respir J, 19:639-44.
58. van Noord JA, Aumann JL, Janssens E, et al. 2005. Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD. Eur Respir J, 26:214-22.
59. Verkindre C, Bart F, Aguilaniu B, et al. 2006. The effect of tiotropium on hyperinflation and exercise capacity in chronic obstructive pulmonary disease. Respiration, 73:420-7.
60. Vincken W, van Noord JA, Greethorst AP, et al. 2002. Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur Respir J, 19:209-16.
61. Voshaar T, Lapidus R, Maleki-Yazdi R, et al. 2008. A randomized study of tiotropium Respimat Soft Mist inhaler vs. ipratropium pMDI in COPD. Respir Med, 102(1):32-41.
62. Wedzicha JA, Calverley PM, Seemungal TA, et al. 2008. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/ fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med, 177:19-26.